Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Inclusion Criteria:

- Informed consent obtained

- Subjects diagnosed with type 2 diabetes and treated with either diet and exercise
alone, metformin, sulphonylurea, glitazone as single agent therapy or a combination of
the previously mentioned compounds

- HbA1c 7.0-10.0% (both inclusive)

- Body Mass Index (BMI) at least 27.0 kg/m^2

- Stable body weight

- Preceding failed dietary effort

Exclusion Criteria:

- Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl
peptidase-4 (DPP-4) inhibitors or insulin within the last 3 months

- Known proliferative retinopathy or maculopathy

- History of acute or chronic pancreatitis

- Obesity induced by drug treatment

- Use of approved weight lowering pharmacotherapy

- Previous surgical treatment of obesity

- History of major depressive disorder or suicide attempt

- Uncontrolled hypertension (systolic blood pressure above or equal to 160 mmHg and/or
diastolic blood pressure above or equal to 100 mmHg)

- Screening calcitonin of 50 ng/L or above

- Familial or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial
medullary thyroid carcinoma (FMTC)

- Personal history of non-familial medullary thyroid carcinoma